• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home StudyGraphics

#VisualAbstract: No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease

byMinjee Kim
December 22, 2023
in StudyGraphics
Reading Time: 2 mins read
#VisualAbstract: No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease
Share on FacebookShare on Twitter

1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated analyses groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The safety of paclitaxel-coated devices for femoropopliteal disease has been well-studied; however, a 2018 meta-analysis raised concerns about increased mortality risk with paclitaxel. This meta-analysis aimed to provide updated insights on data from ten different trials comparing mortality rates between paclitaxel-coated and control (non-paclitaxel-coated) devices. The primary outcome was the effect of paclitaxel exposure on mortality, while key secondary outcomes were the impact of paclitaxel dose and baseline covariates. According to study results, there was no significant increase in mortality between the paclitaxel-coated and non-paclitaxel-coated devices. Although this study was well done, it was limited by variability in trial design and patient populations, affecting the validity of results.

Click to read the study in The Lancet

Relevant Reading: Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

RELATED REPORTS

Borderline-low hemoglobin levels linked to increased mortality

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

In-depth [meta-analysis]: Between 2005 and 2018, 10 trials were included comparing paclitaxel-coated versus control devices for femoropopliteal occlusive disease. Altogether, 2666 patients were included in the final analysis, with a median follow-up of 4.9 years. The primary outcome reported no significant increase in deaths associated with paclitaxel-coated devices (hazard ratio [HR] 1.14, 95% confidence interval [CI] 0.93-1.40). Similarly, the unadjusted HR for all-cause mortality comparing paclitaxel-coated and control-treated participants was 1.02 (95% CI 0.78-1.34), offering reassurance to patients, physicians, and regulators on their safety. Overall, findings from this study suggest that paclitaxel-coated devices do not pose an increased risk of mortality.

 

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: femoropopliteal diseasefemoropopliteal occlusive diseasemortalitypaclitaxelpaclitaxel-coated devices
Previous Post

Elements of religiosity and spirituality help predict clinical response to treatment in adults with mild-to-moderate depression

Next Post

Low eosinophil counts associated with increased acute bacterial infection risk in older adults

RelatedReports

Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
“Housing First” linked to housing stability for homeless youth with mental illness
Public Health

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

August 31, 2026
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Hematologic inflammatory indices may predict prognosis in younger patients with COVID-19 but not older patients

August 4, 2026
Next Post
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Low eosinophil counts associated with increased acute bacterial infection risk in older adults

Prevalence of hypertension among adolescents varies by race and BMI

Elevated systemic inflammation markers associated with increased prevalence of hypertension

UTI associated with increased risk of preeclampsia

Aspirin may slow the progression of abdominal aortic aneurysm

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Few interventions improve posthospitalization follow-up for alcohol use disorder
  • Borderline-low hemoglobin levels linked to increased mortality
  • 2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.